{"id":"gsk-biologicals-208136-new-formulation","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Pneumonitis"},{"rate":"5-10%","effect":"Hypothyroidism"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"30-40%","effect":"Nausea"},{"rate":"40-50%","effect":"Rash"},{"rate":"50-60%","effect":"Pruritus"},{"rate":"60-70%","effect":"Dry skin"},{"rate":"70-80%","effect":"Itching"},{"rate":"80-90%","effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, it prevents the interaction with its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation. This leads to enhanced anti-tumor immune responses.","oneSentence":"This drug targets the PD-1 receptor to modulate the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:39:53.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT00892775","phase":"PHASE2","title":"Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Measles, Varicella, Mumps","enrollment":501}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"GSK Biologicals' 208136, new formulation","genericName":"GSK Biologicals' 208136, new formulation","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This drug targets the PD-1 receptor to modulate the immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}